Search

everythinglearnresearchcommunity

for

Search:↓

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

JAK inhibitors show promise in treating difficult skin diseases.

WYE-130600 may cause skin thickening and irritation.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

The tumor suppressor BRCA2 helps in cell division by bringing key proteins to the area where cells split.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Targeted cancer therapies often cause skin side effects, needing dermatologist care.

Targeted cancer therapies often cause serious skin problems that need careful management.

Overexpressing COX-2 in mice skin reduces skin tumor development.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.

Ca²⁺-mediated protein citrullination controls cell growth in the CNS and may help treat brain tumors.

Pexidartinib often causes liver issues and fatigue, especially in women.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Nilotinib can cause skin issues like red bumps and hair loss.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Imuvert can prevent some chemotherapy-induced hair loss.